Teligent, Inc. Announces Third Quarter 2019 Results

BUENA, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. TLGT, a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2019.

Third Quarter 2019 Highlights

• Net revenues of $18.5 million for the third quarter of 2019, a $0.2 million increase over the same quarter in 2018
   
• Gross margin of 39% for the third quarter of 2019, a 200 basis point increase from the 37% reported in the same quarter of 2018 and year-to-date gross margin of 43%, a 900 basis point increase from the 34% reported for the same nine month period in 2018, primarily driven by favorable customer and product mix
   
• $2.1 million of product development and research expenses in the third quarter of 2019, compared to $3.1 million for the same quarter in 2018
   
• Operating income was $0.2 million for the third quarter of 2019, an improvement of $1.4 million over the operating loss of $1.2 million reported in the same quarter of 2018
   
• As a result of the fluctuation in foreign exchange rates during the third quarter of 2019, the Company recorded a non-cash loss in the amount of $2.2 million related to the foreign currency translation of its intercompany loans and other balances held in foreign currencies, as compared to a non-cash loss in the amount of $0.2 million in the same quarter of 2018
   
• Adjusted EBITDA was $2.1 million in the third quarter of 2019, reflecting an improvement of $1.5 million compared to $0.6 million in the same quarter of 2018

"For the second consecutive quarter, Teligent reported revenues exceeding $18 million and positive Adjusted EBITDA. We also realized a year-to-date gross margin of 43%," said Jason Grenfell-Gardner, President and Chief Executive Officer.

Mr. Grenfell-Gardner continued, "Since the end of the third quarter, we announced our strategic review of non-core assets, received approval for Gentamicin Sulfate Cream USP 0.1%, issued $34.4 million of convertible bonds, and most importantly, filed a prior approval supplement for ranitidine hydrochloride injection. These actions, coupled with our third quarter financial results, are critical components and solid evidence that we continue to forge the path to profitable growth."

Mr. Grenfell-Gardner concluded, "We remain confident in achieving gross margins in excess of 40% for the full year, are well-positioned to deliver adjusted EBITDA margins in excess of 10% for the full year, and with a strong fourth quarter, we project revenues of $68.5 million to $72.5 million for the full year."

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Forward-Looking Statements

This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue," "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to successfully complete future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in Teligent, Inc.'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Non-GAAP Financial Measures

In addition to reporting financial information required in accordance with U.S. generally accepted accounting principles (GAAP), Teligent is also presenting EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research which are non-GAAP financial measures. Since EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs are non-GAAP financial measures, they should not be used in isolation or as a substitute for consolidated statements of operations and cash flow data prepared in accordance with GAAP. In addition, Teligent's definition of Adjusted EBITDA and adjusted net loss  may not be comparable to similarly titled non-GAAP financial measures reported by other companies.

Adjusted EBITDA, as defined by the Company, is calculated as follows:

Net loss, plus:

Depreciation expense

Amortization of intangibles

Impairment losses

Interest expense, net

Amortization of debt issuance costs, debt discounts and debt extinguishment

Provision for income taxes

Foreign currency exchange gain/(loss)

Non-cash stock-based compensation expense

The Company believes that Adjusted EBITDA is a meaningful indicator, to both Company management and investors, of the past and expected ongoing operating performance of the Company. EBITDA is a commonly used and widely accepted measure of financial performance. Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash and non-recurring operating expenses which have little to no bearing on cash flows and may be subject to uncontrollable factors not reflective of the Company's true operational performance.

While the Company uses EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs in managing and analyzing its business and financial condition and believes these non-GAAP financial measures to be useful to investors in evaluating the Company's performance, it is open to certain shortcomings. EBITDA and Adjusted EBITDA do not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company and likewise omit share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense.  Due to the inherent limitations of EBITDA, Adjusted EBITDA and Adjusted EBITDA before product development and research costs, the Company's management utilizes comparable GAAP financial measures to evaluate the business in conjunction with EBITDA and Adjusted EBITDA and encourages investors to do likewise.

The Company also presents a non-GAAP financial measure of adjusted net income (loss) and adjusted net income (loss) per diluted share, to show the adjusted net income when EBITDA adjustments are added back or subtracted out of the traditional GAAP reported net income (loss).  Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income divided by the actual or anticipated diluted share count for the applicable period.